BPC-157 & TB-500 — the repair pair
The two most-asked-about peptides in tissue-repair research target different pieces of the same biology. BPC-157 is a synthetic fragment derived from a gastric protective protein that appears to modulate angiogenesis, growth-factor signaling, and the nitric-oxide axis. TB-500 is a synthetic version of the active region of thymosin-β4, an actin-sequestering protein involved in cell migration. Researchers commonly study them together because their mechanisms overlap minimally — they hit angiogenesis from two different angles.
BPC-157 — pentadecapeptide 15
- Sequence: 15 amino acids — GEPPPGKPADDAGLV — a synthetic stable fragment of body protection compound from human gastric juice.
- Molecular weight: ~1419 Da.
- Proposed mechanism: upregulates VEGFR2 and nitric-oxide synthase pathways, modulates growth-hormone receptor expression on fibroblasts, accelerates angiogenesis at injury sites in animal models.
- Half-life: short in plasma (minutes) but biological effects in research models persist much longer, suggesting tissue-binding or downstream cascades.
- Stability: unusually robust — survives gastric pH, which is why oral and injectable preparations both exist.
Oral vs injectable BPC-157
| Form | Typical research dose | Onset | Used for |
|---|---|---|---|
| Subcutaneous injection | 250–500 µg, 1–2× daily | Hours | Systemic / soft-tissue research |
| Oral capsule / dissolvable strip | 500 µg, 1–2× daily | Hours (gut-localized first-pass) | GI-mucosal research models |
| Local injection (near injury site) | 250 µg | Direct tissue exposure | Tendon / ligament research models |
TB-500 — thymosin-β4 fragment
- Sequence: 17 amino acids — LKKTETQ + flanking residues — the actin-binding core of full-length Tβ4.
- Molecular weight: ~1894 Da.
- Proposed mechanism: sequesters G-actin to maintain a polymerization-ready pool, supports cell migration, modulates angiogenesis and inflammation at injury sites.
- Half-life: hours in plasma; research dosing is typically 2–3 mg twice weekly in a loading phase, then weekly.
- Stability: standard cold-chain peptide — reconstituted vials stable 30+ days at 2–8 °C in BAC water.
Why they're often stacked in research
The two compounds approach repair biology from non-overlapping directions:
- BPC-157 emphasizes signaling — growth-factor receptor upregulation, nitric-oxide modulation, fibroblast behavior.
- TB-500 emphasizes cytoskeletal mobility — making cells more migratory so they can populate an injury site.
- Together, research protocols pair BPC-157 daily (for sustained signaling) with TB-500 twice weekly (loading) then weekly (maintenance).
Reconstitution and storage
BPC-157 5 mg vial reconstituted with 2.5 mL BAC water → 2 mg/mL. A 250 µg dose = 0.125 mL = 12.5 units on a U-100 syringe. TB-500 5 mg vial reconstituted with 2.5 mL BAC water → 2 mg/mL. A 2.5 mg loading dose = 1.25 mL = 125 units. Both peptides follow the cold-chain rules in the storage & handling guide — full per-vial reconstitution math is in the dosage protocols guide.
Safety, risks & legal notice
Read before ordering or conducting any research
For laboratory research only
Every compound described on this page is sold and provided strictly as a research-grade reagent for in-vitro and animal-model studies. These products are not intended for human consumption, cosmetic use, dietary supplementation, or any clinical or therapeutic application. By purchasing, you represent that you are a qualified researcher, laboratory, or educational institution with appropriate facilities and oversight.
Not FDA-approved or evaluated
None of the compounds on this page have been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent bodies for the indications discussed in research contexts. Safety and efficacy profiles in humans are unknown, incompletely characterized, or based solely on pre-clinical and investigator-initiated studies.
No medical, clinical, or dosing advice
Dr Jays Peptides does not employ physicians, pharmacists, or clinical researchers. Nothing on this page — including dosage figures, reconstitution math, or mechanism descriptions — constitutes medical advice, a prescribing recommendation, or instructions for self-administration. If you are considering any peptide for personal use, consult a licensed healthcare provider who can evaluate your individual risk factors, medication interactions, and monitoring needs.
Class-specific risk signals
- Angiogenesis and tumor growth: both BPC-157 and TB-500 upregulate angiogenesis (VEGF, VEGFR2). In research models with existing neoplasia, pro-angiogenic compounds may theoretically accelerate tumor vascularization and growth. This is a major reason human clinical trials have not advanced for either peptide.
- Limited human safety data: no Phase I–III trials, no official pharmacovigilance databases, and no long-term exposure cohorts exist. Almost all safety knowledge comes from animal models and anecdotal reports.
- Immunogenicity: BPC-157 is a synthetic fragment of a human gastric protein, but it is not identical to the native sequence; antibody formation has not been systematically studied.
- Oral bioavailability uncertainty: while BPC-157 survives gastric pH in vitro, actual absorption fractions, first-pass metabolism, and systemic exposure after oral dosing are poorly quantified in peer-reviewed studies.
- WADA / sporting ban: both peptides are explicitly listed on the WADA Prohibited List. Athletes subject to testing must avoid them entirely.
Prohibited by WADA and most sporting bodies
Compounds in this class are explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). They are also banned by the IOC, NCAA, USADA, UKAD, and virtually all national anti-doping agencies. Athletes subject to drug testing should not purchase, possess, or use these substances.
General risk factors
- Purity and contamination: Research peptides are not manufactured to pharmaceutical-grade GMP standards. Even high-purity lots may contain trace endotoxins, residual solvents, or unrelated peptide sequences.
- Stability and degradation: Improper storage, repeated freeze–thaw cycles, or use beyond recommended reconstitution windows can produce degraded products with unknown toxicology.
- Immunogenicity: Foreign peptides can elicit antibody responses; repeated administration may cause allergic reactions or neutralizing antibodies that alter pharmacokinetics in unpredictable ways.
- Drug interactions: Peptides may potentiate or antagonize prescription medications, herbal supplements, or other research compounds. No systematic interaction data exists for most of these molecules.
- Pregnancy, lactation, and pediatric populations: Zero safety data. Absolute contraindication for use in these populations.
Legal status & buyer responsibility
The legal status of research peptides varies by country, state, and municipality. It is the buyer's sole responsibility to understand and comply with all applicable laws, regulations, and institutional policies in their jurisdiction before ordering. Dr Jays Peptides ships products with accurate customs declarations; buyers are responsible for any import duties, inspections, or seizures. We reserve the right to cancel any order where we believe the buyer lacks legitimate research intent or where shipment would violate local law.
Limitation of liability: To the maximum extent permitted by law, Dr Jays Peptides and its affiliates, suppliers, and agents disclaim all liability for any injury, illness, adverse reaction, or loss arising from the purchase, handling, or use of any product described on this page. This includes liability for negligence, product defect, mislabeling, or failure to warn. By proceeding with a purchase, you agree to indemnify and hold harmless Dr Jays Peptides from any claims, damages, or expenses related to your research activities.